Therapeutics News and Research

RSS
Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Fero Industries to acquire Pyro Pharmaceuticals

Fero Industries to acquire Pyro Pharmaceuticals

Postive vote from FDA Advisory Committee for Fampridine-SR 10

Postive vote from FDA Advisory Committee for Fampridine-SR 10

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Presentation on L-DOS47 drug formulation and development at Pharmaceutical Industry Conference

Presentation on L-DOS47 drug formulation and development at Pharmaceutical Industry Conference

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

2010 TIPPS certification for Prime Therapeutics

2010 TIPPS certification for Prime Therapeutics

Cequent Pharmaceuticals to provide details of its clinical program at BIOCOM conference

Cequent Pharmaceuticals to provide details of its clinical program at BIOCOM conference

Case Western Reserve University receives a $20.5M gift to support medical education and research programs

Case Western Reserve University receives a $20.5M gift to support medical education and research programs

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

SAFC Pharma expands contract manufacturing services

SAFC Pharma expands contract manufacturing services

Amsterdam Molecular Therapeutics' AMT-080 granted EMEA Orphan Drug Designation

Amsterdam Molecular Therapeutics' AMT-080 granted EMEA Orphan Drug Designation

ImaginAb and BZL Biologics conclude sublicense agreement for antibody technology

ImaginAb and BZL Biologics conclude sublicense agreement for antibody technology

CED to host popular STREAK program

CED to host popular STREAK program

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Heptares Therapeutics to apply its StaR technology to generate novel drug leads against GPCR target

Pieris reports its progress in the development of PRS-050

Pieris reports its progress in the development of PRS-050

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms